CanSino (688185.SH): DTcP-Hib-MCV4 combination vaccine initiates phase I clinical trial and completes the enrollment of the first subject

Zhtng Cijng APP News, Kangxinuo (688185.SH) released an announcement that the company's adjuvant-free cell-free combined b-type influenza hemoxyphilic rod bacterium (binding)-ACYW135 group meningococcal (binding) combined vaccine (referred to as "DTcP-Hib-MCV4 combined vaccine") has officially started Phase I clinical trials recently, and the first subject has been successfully enrolled.